There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS.
Read Article
Antoni Chan, PhD, FRCP, is a Consultant Rheumatologist and Associate Medical Director at the Royal Berkshire NHS Foundation Trust, Reading, United Kingdom. He is a full member of ASAS. He won the British Society for Rheumatology Best Practice Award for developing a new integrated pain service. In 2018 he received the Patient Choice Award for Best Care by a Rheumatologist from the National Ankylosing Spondylitis Society. He leads the Axial Spondyloarthritis service in his hospital and the team were awarded the NASS Aspiring to Excellence Award in 2019. Follow him on Twitter @synovialjoints.